Tumor immunomodulation mechanism after carbon ion beam irradiation on pancreatic cancer cells
| Project/Area Number |
16K19806
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | Gunma University |
|---|
Principal Investigator |
|
|---|
| Research Collaborator |
Murata Hiroto
|
|---|
| Project Period (FY) |
2016-04-01 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 放射線治療 / 重粒子線治療 / PD-L1 / 放射線 / 重粒子線 / 腫瘍免疫 / 膵癌 |
|---|
| Outline of Final Research Achievements |
The expression of PD-L1 after irradiation (X-ray /carbon ion beam) was verified using pancreatic cancer cells, gastric cancer cells, head and neck squamous cell carcinoma cells, malignant melanoma cells, and lung cancer cells. No increase in PD-L1 expression was observed even after the conditions such as the time course were changed. But the irradiation dose-dependent increase of PD-L1 was confirmed at the human osteosarcoma cell line U2OS by Western blot and flow cytometry. In certain carcinomas, it is speculated that radiation enhances the expression of PD-L1, which contributes to the acquisition of resistance to radiation therapy.
|
| Academic Significance and Societal Importance of the Research Achievements |
今回の研究の当初の目的であった膵癌細胞では放射線によるPD-L1の発現増加は確認されなかったが、特定の癌腫（骨肉腫細胞）においては放射線照射によりPD-L1の発現が亢進されることが確認された。PD-L1の発現亢進は腫瘍免疫の抑制に繋がり、治療抵抗性の一因となり得る。即ち放射線治療と免疫チェックポイント治療の併用により、放射線治療抵抗性である骨肉腫等に対して、より強い治療効果が得られる可能性が示唆された。
|
Report
(4 results)
Research Products
(4 results)
